awmsg logo



empagliflozin (Jardiance®)


Reference No. 2746

Publication date:
12/01/2016


Appraisal information

empagliflozin (Jardiance®) 10 mg film-coated tablet
empagliflozin (Jardiance®) 25 mg film-coated tablet


Company: Boehringer Ingelheim Ltd
BNF category: Endocrine system
NMG meeting date: 04/11/2015
AWMSG meeting date: 09/12/2015
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 3915
Ministerial ratification: 11/01/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA390) NICE GUIDANCE ISSUED MAY 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Empagliflozin (Jardiance®) is recommended as an option for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download